(Q43036320)

12 November 2017

title

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study (English)

1 reference

12 November 2017

1

1 reference

12 November 2017

6

1 reference

12 November 2017

13

1 reference

12 November 2017

2

Tommaso Stroffolini

1 reference

12 November 2017

14

Stefano Fagiuoli

1 reference

12 November 2017

Massimo Colombo

3

1 reference

12 November 2017

Simona Bollani

4

1 reference

12 November 2017

Luisa Benvegnù

5

1 reference

12 November 2017

Antonio Ascione

7

1 reference

12 November 2017

Teresa Santantonio

8

1 reference

12 November 2017

Felice Piccinino

9

1 reference

12 November 2017

Pietro Andreone

10

1 reference

12 November 2017

Alessandra Mangia

11

1 reference

12 November 2017

Giovanni B Gaeta

12

1 reference

12 November 2017

Piero L Almasio

15

1 reference

12 November 2017

Italian Association of the Study of the Liver Disease (AISF)

16

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

12 November 2017

1 reference

12 November 2017

volume

45

1 reference

12 November 2017

issue

3

1 reference

12 November 2017

page(s)

579-587

1 reference

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

12 November 2017

cites work

1 reference

Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival

21 January 2018

1 reference

Interferon-alpha in chronic hepatitis C.

21 January 2018

1 reference

Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study

21 January 2018

1 reference

Prevention of hepatitis C virus-related hepatocellular carcinoma

21 January 2018

1 reference

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

7 January 2021

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

1 reference

7 January 2021

Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.

1 reference

7 January 2021

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

1 reference

7 January 2021

Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy

1 reference

7 January 2021

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

1 reference

7 January 2021

Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group

1 reference

7 January 2021

Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy

1 reference

7 January 2021

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach

1 reference

7 January 2021

Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis

1 reference

7 January 2021

The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis.

1 reference

7 January 2021

Histological features and clinical course of large regenerative nodules: Evaluation of their precancerous potentiality

1 reference

7 January 2021

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

7 January 2021

Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

7 January 2021

Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study

1 reference

7 January 2021

Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study

1 reference

7 January 2021

Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse

1 reference

7 January 2021

Management of hepatocellular carcinoma

1 reference

7 January 2021

Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications

1 reference

7 January 2021

The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients

1 reference

7 January 2021

Involvement of IL-1beta and IL-10 in IFN-alpha-mediated antiviral gene induction in human hepatoma cells

1 reference

7 January 2021

IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat.

1 reference

7 January 2021

Long-term high-dose interferon-α therapy delays Hepadnavirus-related hepatocarcinogenesis in X/myc transgenic mice

1 reference

7 January 2021

Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.

1 reference

7 January 2021

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

1 reference

7 January 2021

American Gastroenterological Association medical position statement on the management of hepatitis C

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21492

1 reference

12 November 2017

1 reference